; Vaquero, Javier
; Saborowski, Anna
; Fabris, Luca ; Rodrigues, Pedro M.
; Coulouarn, Cédric ; Castro, Rui E.
; Segatto, Oreste ; Raggi, Chiara ; van der Laan, Luc J. W.
; Carpino, Guido ; Goeppert, Benjamin ; Roessler, Stephanie ; Kendall, Timothy J.
; Evert, Matthias ; Gonzalez-Sanchez, Ester
; Valle, Juan W. ; Vogel, Arndt ; Bridgewater, John ; Borad, Mitesh J. ; Gores, Gregory J. ; Roberts, Lewis R.
; Marin, Jose J. G.
; Andersen, Jesper B. ; Alvaro, Domenico ; Forner, Alejandro ; Banales, Jesus M.
; Cardinale, Vincenzo
; Macias, Rocio I. R. ; Vicent, Silve ; Chen, Xin ; Braconi, Chiara ; Verstegen, Monique M. A.
; Fouassier, Laura
; Roberts, Lewis
; Scheiter, Alexander ; Selaru, Florin M. ; Evert, Katja ; Utpatel, Kirsten ; Broutier, Laura ; Cadamuro, Massimiliano
; Huch, Meritxell ; Goldin, Robert
; Gradilone, Sergio A.
; Saito, Yoshimasa | Item type: | Article | ||||
|---|---|---|---|---|---|
| Journal or Publication Title: | Nature Reviews Gastroenterology & Hepatology | ||||
| Publisher: | NATURE PORTFOLIO | ||||
| Place of Publication: | BERLIN | ||||
| Volume: | 20 | ||||
| Number of Issue or Book Chapter: | 7 | ||||
| Page Range: | pp. 462-480 | ||||
| Date: | 2023 | ||||
| Institutions: | Medicine > Lehrstuhl für Pathologie | ||||
| Identification Number: |
| ||||
| Keywords: | INTRADUCTAL PAPILLARY NEOPLASMS; PATIENT DERIVED XENOGRAFT; MUCINOUS CYSTIC NEOPLASMS; PRIMARY LIVER-CANCER; BILE-DUCT; INTRAHEPATIC CHOLANGIOCARCINOMA; PROMOTES CHOLANGIOCARCINOMA; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; MOUSE MODEL; | ||||
| Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||
| Status: | Published | ||||
| Refereed: | Yes, this version has been refereed | ||||
| Created at the University of Regensburg: | Yes | ||||
| Item ID: | 76307 |
Abstract
Preclinical research is required to improve our understanding of cholangiocarcinoma (CCA). In this Consensus Statement, a task force of experts provides recommendations on the criteria for preclinical models of CCA to increase disease understanding and help to develop novel therapeutic approaches. Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA ...

Abstract
Preclinical research is required to improve our understanding of cholangiocarcinoma (CCA). In this Consensus Statement, a task force of experts provides recommendations on the criteria for preclinical models of CCA to increase disease understanding and help to develop novel therapeutic approaches. Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. Therefore, preclinical research is of pivotal importance and necessary to acquire a deeper understanding of CCA and improve therapeutic outcomes. Preclinical research involves developing and managing complementary experimental models, from in vitro assays using primary cells or cell lines cultured in 2D or 3D to in vivo models with engrafted material, chemically induced CCA or genetically engineered models. All are valuable tools with well-defined advantages and limitations. The choice of a preclinical model is guided by the question(s) to be addressed; ideally, results should be recapitulated in independent approaches. In this Consensus Statement, a task force of 45 experts in CCA molecular and cellular biology and clinicians, including pathologists, from ten countries provides recommendations on the minimal criteria for preclinical models to provide a uniform approach. These recommendations are based on two rounds of questionnaires completed by 35 (first round) and 45 (second round) experts to reach a consensus with 13 statements. An agreement was defined when at least 90% of the participants voting anonymously agreed with a statement. The ultimate goal was to transfer basic laboratory research to the clinics through increased disease understanding and to develop clinical biomarkers and innovative therapies for patients with CCA.
Metadata last modified: 18 Mar 2025 10:11
Altmetric